María Fernanda Ponce-Beti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
María Fernanda Ponce-Beti has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Elena Martín-García
Laboratory of Neuropharmacology-Neurophar, Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain
2 shared publications - Rafael Maldonado
Laboratory of Neuropharmacology-Neurophar, Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain
2 shared publications - Roberto Capellán
Laboratory of Neuropharmacology-Neurophar, Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain
2 shared publications - Tatiana Gusinskaia
Laboratory of Neuropharmacology-Neurophar, Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain
2 shared publications - Bru Cormand
Universitat de Barcelona
1 shared publication - Edurne Gago-García
Departament de Genètica, Microbiologia i Estadística, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain
1 shared publication
Latest Publications
- Open Access
Distinct Glutamatergic Inputs to the Nucleus Accumbens Differentially Regulate Vulnerability to Cannabinoid Addiction
Cannabis use disorder (CUD) is a chronic relapsing disorder characterized by compulsive drug seeking, persistent drug use despite adverse consequences, and a high risk of relapse. Although the nucleus accumbens (NAc) is a central hub in the neural circuitry underlying addiction, the specific glutamatergic inputs regulating vulnerability to cannabinoid addiction remain poorly understood. Here, we investigated the contribution of two major limbic glutamatergic projections to the NAc, the dorsal hippocampus (dHPC) to NAc and basolateral amygdala (BLA) to NAc pathways, using a validated mouse model of WIN55,212-2 intravenous self-administration combined with projection-specific chemogenetic inhibition. Male C57BL/6J mice received combinatorial viral vector delivery of inhibitory hM4Di DREADDs selectively targeting either the dHPC to NAc or the BLA to NAc pathway. Chronic pathway inhibition was achieved by continuous administration of deschloroclozapine through osmotic minipumps during the development of cannabinoid addiction-like behavior. Animals were evaluated using a multidimensional behavioral paradigm assessing the three-core addiction-like criteria of persistence of drug seeking, motivation, and compulsive-like behavior, as well as craving-related behaviors and phenotypic vulnerability traits. Chronic inhibition of either the dHPC to NAc or the BLA to NAc pathway significantly increased the proportion of mice developing an addiction-like phenotype. Both manipulations enhanced persistence of drug seeking during periods of drug unavailability, identifying persistence as a shared behavioral consequence of disrupting glutamatergic signaling to the NAc. In contrast, the two pathways differentially regulated other addiction-related behaviors. Inhibition of the dHPC to NAc pathway increased motivation to obtain WIN55,212-2, impulsivity, reward sensitivity, and resistance to extinction, whereas inhibition of the BLA to NAc pathway selectively enhanced cue-induced drug seeking. Neither manipulation altered compulsive-like responding, locomotor activity, or body weight. These findings demonstrate that distinct glutamatergic afferents to the NAc differentially regulate vulnerability to cannabinoid addiction-like behavior while converging on persistence as a common circuit-level mechanism. Our results establish the NAc as an integrative hub coordinating complementary contextual and emotional information during the transition to cannabinoid addiction and provide a circuit-based framework for understanding the neural mechanisms underlying Cannabis Use Disorder.
Open AccessDistinct Glutamatergic Inputs to the Nucleus Accumbens Differentially Regulate Vulnerability to Cannabinoid Addiction
Cannabis use disorder (CUD) is a chronic relapsing disorder characterized by compulsive drug seeking, persistent drug use despite adverse consequences, and a high risk of relapse. Although the nucleus accumbens (NAc) is a central hub in the neural circuitry underlying addiction, the specific glutamatergic inputs regulating vulnerability to cannabinoid addiction remain poorly understood. Here, we investigated the contribution of two major limbic glutamatergic projections to the NAc, the dorsal hippocampus (dHPC) to NAc and basolateral amygdala (BLA) to NAc pathways, using a validated mouse model of WIN55,212-2 intravenous self-administration combined with projection-specific chemogenetic inhibition. Male C57BL/6J mice received combinatorial viral vector delivery of inhibitory hM4Di DREADDs selectively targeting either the dHPC to NAc or the BLA to NAc pathway. Chronic pathway inhibition was achieved by continuous administration of deschloroclozapine through osmotic minipumps during the development of cannabinoid addiction-like behavior. Animals were evaluated using a multidimensional behavioral paradigm assessing the three-core addiction-like criteria of persistence of drug seeking, motivation, and compulsive-like behavior, as well as craving-related behaviors and phenotypic vulnerability traits. Chronic inhibition of either the dHPC to NAc or the BLA to NAc pathway significantly increased the proportion of mice developing an addiction-like phenotype. Both manipulations enhanced persistence of drug seeking during periods of drug unavailability, identifying persistence as a shared behavioral consequence of disrupting glutamatergic signaling to the NAc. In contrast, the two pathways differentially regulated other addiction-related behaviors. Inhibition of the dHPC to NAc pathway increased motivation to obtain WIN55,212-2, impulsivity, reward sensitivity, and resistance to extinction, whereas inhibition of the BLA to NAc pathway selectively enhanced cue-induced drug seeking. Neither manipulation altered compulsive-like responding, locomotor activity, or body weight. These findings demonstrate that distinct glutamatergic afferents to the NAc differentially regulate vulnerability to cannabinoid addiction-like behavior while converging on persistence as a common circuit-level mechanism. Our results establish the NAc as an integrative hub coordinating complementary contextual and emotional information during the transition to cannabinoid addiction and provide a circuit-based framework for understanding the neural mechanisms underlying Cannabis Use Disorder.
- Open Access
Sex-specific vulnerability to cannabinoid addiction-like behavior and associated miRNA signatures in a WIN 55,212-2 self-administration mouse model
Cannabis is one of the most widely used psychoactive substances worldwide, and cannabis use disorder (CUD) is increasingly recognized as a major public health concern. Clinical evidence indicates that women may be particularly vulnerable to developing addiction, exhibiting a faster transition from initial drug use to loss of control and increased relapse vulnerability. However, females remain underrepresented in both preclinical and clinical research, limiting our understanding of the neurobiological mechanisms underlying this susceptibility. Here, we investigated sex differences in behavioral and epigenetic susceptibility to cannabinoid addiction using a mouse operant self-administration model with the synthetic cannabinoid agonist WIN 55,212-2. Female mice displayed increased addiction-like behavior, characterized by greater persistence of responding during drug-free periods and enhanced compulsive-like drug seeking compared to males. miRNA profiling in the medial prefrontal cortex (mPFC) identified a female-specific epigenetic signature associated with the addiction-like phenotype, including downregulation of mmu-miR-669j, mmu-miR-7036b-5p, mmu-miR-878-3p, and mmu-miR-7017-3p, together with upregulation of mmu-miR-3092-5p in addicted females. Functional enrichment analyses of predicted target genes revealed pathways related to synaptic organization, axon guidance, neurotransmission, and structural plasticity. Together, these findings demonstrate sex-dependent differences in vulnerability to cannabinoid addiction-like behavior and identify a specific miRNA signature in the mPFC associated with this phenotype, highlighting potential targets for the development of sex-specific therapeutic strategies.
Open AccessSex-specific vulnerability to cannabinoid addiction-like behavior and associated miRNA signatures in a WIN 55,212-2 self-administration mouse model
Cannabis is one of the most widely used psychoactive substances worldwide, and cannabis use disorder (CUD) is increasingly recognized as a major public health concern. Clinical evidence indicates that women may be particularly vulnerable to developing addiction, exhibiting a faster transition from initial drug use to loss of control and increased relapse vulnerability. However, females remain underrepresented in both preclinical and clinical research, limiting our understanding of the neurobiological mechanisms underlying this susceptibility. Here, we investigated sex differences in behavioral and epigenetic susceptibility to cannabinoid addiction using a mouse operant self-administration model with the synthetic cannabinoid agonist WIN 55,212-2. Female mice displayed increased addiction-like behavior, characterized by greater persistence of responding during drug-free periods and enhanced compulsive-like drug seeking compared to males. miRNA profiling in the medial prefrontal cortex (mPFC) identified a female-specific epigenetic signature associated with the addiction-like phenotype, including downregulation of mmu-miR-669j, mmu-miR-7036b-5p, mmu-miR-878-3p, and mmu-miR-7017-3p, together with upregulation of mmu-miR-3092-5p in addicted females. Functional enrichment analyses of predicted target genes revealed pathways related to synaptic organization, axon guidance, neurotransmission, and structural plasticity. Together, these findings demonstrate sex-dependent differences in vulnerability to cannabinoid addiction-like behavior and identify a specific miRNA signature in the mPFC associated with this phenotype, highlighting potential targets for the development of sex-specific therapeutic strategies.